Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - histidinum inn; phenylalaninum inn; leucinum inn; tyrosinum inn; serinum inn; lysinum inn; cysteinum inn; glycinum inn; prolinum inn; tryptophanum inn; methioninum inn; threoninum inn; isoleucinum inn; taurinum inn; acidum glutamicum inn; valinum inn; argininum inn; acidum asparticum inn; alaninum inn - innrennslislyf, lausn

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vericel denmark aps - autologous cultured chondrocytes - brot, brjósk - Önnur lyf við sjúkdómum í stoðkerfi - viðgerðir á brjóskum á brjósti á einkennum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - Ónæmisbælandi lyf - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati rare diseases - merkaptamín bítartrat - cystinosis - Önnur meltingarvegi og efnaskipti vörur, - cystagon er ætlað til meðferðar á sannaðri nýrnasjúkdómssýkingu. cysteamín dregur úr uppsöfnun cystíns í sumum frumum (e. hvítfrumum, vöðvum og lifrarfrumum) hjá sjúklingum með nýrnasjúkdóm í blöðruhálskirtli og þegar meðferð er hafin í byrjun, seinkar það þróun nýrnabilunar.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - merkaptamín bítartrat - cystinosis - Önnur meltingarvegi og efnaskipti vörur, - procysbi er ætlað til meðferðar á sannaðri nýrnasjúkdómssýkingu. cysteamín dregur úr uppsöfnun cystíns í sumum frumum (e. hvítfrumum, vöðvum og lifrarfrumum) hjá sjúklingum með nýrnasjúkdóm í blöðruhálskirtli og þegar meðferð er hafin í byrjun, seinkar það þróun nýrnabilunar.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati rare diseases - betaine vatnsfrítt - homocystinuria - Önnur meltingarvegi og efnaskipti vörur, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl). cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

serb sa - betaine - homocystinuria - Önnur meltingarvegi og efnaskipti vörur, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (cbs),•         5,10 methylene tetrahydrofolate reductase (mthfr),•         cobalamin cofactor metabolism (cbl).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - Önnur öndunarfæri - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - Önnur öndunarfæri - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystic fibrosis - Önnur öndunarfæri - orkambi töflur eru ætlað til meðferð fá lungnasjúkdóm (samanber) í sjúklinga á aldrinum 6 ára og eldri sem eru tilbúin fyrir f508del stökkbreytingu í cftr gene. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.